Emergent BioSolutions Stock
Emergent BioSolutions Inc.
Company data
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Country
- United States
- CEO
- Joseph C. Papa Jr.
- Employees
- 900
- Market cap
- $327 M
- IPO
- 15/11/2006
Emergent BioSolutions Inc. is a life sciences company dedicated to providing vital preparedness and response solutions for a wide range of public health threats (PHTs) across the United States. These threats encompass accidental, deliberate, and naturally occurring events, including chemical, biological, radiological,…
Emergent BioSolutions stock: price history
1D
-11.1%
1W
-9.6%
1M
-5.5%
6M
-27.6%
YTD
-48.4%
1Y
-32.1%
2Y
-30.3%
5Y
-87.4%
10Y
-78.2%
Next earnings date
Next earnings date
02/11/2026 (in 16 days)
Volatility around earnings
~220% stronger price swings than usual
Ask the agents about Emergent BioSolutions
Analyst assessment of Emergent BioSolutions
PRICE TARGET LOW
US$10.00
CONSENSUS
US$10.00
MEDIAN
US$10.00
PRICE TARGET HIGH
US$10.00
0
STRONG BUY
11
BUY
3
HOLD
1
SELL
0
STRONG SELL
15
TOTAL · Buy
As of: 09/09/2026
Emergent BioSolutions stock metrics
P/E
-1.85
P/B
0.96
EV/EBITDA
-1,098.89
RETURN ON EQUITY
-52.8%
NET MARGIN
-76.9%
DEBT/EQUITY
1.7
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
95.7%
FLOAT SHARES
49,050,637
AVG. DAILY VOLUME (30D)
1,154,435
Insider transactions (SEC)
DeGolyer Donald W
Williams Paul Anthony
Williams Paul Anthony
Williams Paul Anthony
Hartzel William
Attention
1 mention today in US forums, 75% fewer than yesterdayPrice since yesterday: -11.1%
Forums (Reddit)
Institutional holders
Comparable stocks
Frequently asked questions about Emergent BioSolutions stock
What does Emergent BioSolutions do?
Emergent BioSolutions Inc. is a company in the Healthcare sector, Drug Manufacturers - Specialty & Generic industry, headquartered in United States.
The CEO is Joseph C. Papa Jr., the company employs around 900 people.
The IPO was on 15/11/2006; the stock trades on NYSE under the ticker EBS.
What do analysts say about Emergent BioSolutions stock?
15 analysts rate the stock, the consensus is Buy (as of 09/09/2026).
The average price target is US$10.00, ranging from US$10.00 to US$10.00, with a median of US$10.00.
This is an external assessment, not a statement by Market Jury.
When does Emergent BioSolutions report next?
The next earnings date is 02/11/2026.
Around past earnings, price swings were roughly 220% stronger than usual.
Does Emergent BioSolutions pay a dividend?
No, Emergent BioSolutions currently does not pay a dividend.
Which stocks are comparable to Emergent BioSolutions?
Comparable stocks include Zoetis, Viatris, Lantheus Holdings, Amneal Pharmaceuticals, Indivior Pharmaceuticals, Eton Pharmaceuticals, Pacira BioSciences and Amphastar Pharmaceuticals.
How can I get Emergent BioSolutions stock analyzed?
Clicking "Analyze stock" lets five strategies assess Emergent BioSolutions against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.